Life Sciences
BlueRock Therapeutics will utilize Rune Labs' StriveStudy clinical trial platform and FDA-cleared Apple Watch data-collection tool to monitor Parkinson's disease.
HIMSS23
Wendy Paul, medication process architect at Seattle Children's Hospital, and Kyle Longhurst, product manager at Pariveda, preview their HIMSS23 discussion on a discharge medication error quality improvement project.
Epigenetic profiling creates opportunities for healthcare and the development of new drugs based on it, according to Mohamad Takwa, CEO of Epigenica, a Sweden-based company that focuses on the technology.
Also, EpiSoft announces the integration of its cancer management platform with My Health Record.
The multinational pharma company will access Tempus' AI-enabled data library to further therapeutic development and advance its portfolio in oncology.
DenovAI will create an AI-powered platform to discover potential antibodies from scratch, then suggest which ones can be used as effective drugs.
Lucira's diagnostic is the first over-the-counter at-home combination test for COVID-19 and flu authorized by the FDA.
The Copenhagen-based digital health company will work with Novartis to build digital health tools for chronic conditions where they see unmet needs and the potential for disease progression.
Diathrive Health users will have access to Mark Cuban Cost Plus Drug Company's lower-cost diabetes medication and testing supplies.
A look ahead with Judy Jiao, CIO of National Government Services, who also gives insights on precision medicine advancements and more.